[{"id":"5351b2fd-adc5-41e4-92bd-076122f48c07","acronym":"BRI-ROL-001","url":"https://clinicaltrials.gov/study/NCT03328026","created_at":"2021-01-18T16:26:04.427Z","updated_at":"2025-02-25T16:52:02.280Z","phase":"Phase 1/2","brief_title":"Combination Study of SV-BR-1-GM With Retifanlimab","source_id_and_acronym":"NCT03328026 - BRI-ROL-001","lead_sponsor":"BriaCell Therapeutics Corporation","biomarkers":" ER • PIK3CA • PGR","pipe":" | ","alterations":" HER-2 positive • HER-2 negative • PGR positive","tags":["ER • PIK3CA • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Zynyz (retifanlimab-dlwr) • epacadostat (INCB024360) • Bria-IMT (SV-BR-1-GM) • Intron A (interferon α-2b) • cyclophosphamide intravenous"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 36","initiation":"Initiation: 03/16/2018","start_date":" 03/16/2018","primary_txt":" Primary completion: 11/03/2025","primary_completion_date":" 11/03/2025","study_txt":" Completion: 11/30/2028","study_completion_date":" 11/30/2028","last_update_posted":"2025-02-04"},{"id":"971d9282-8be3-4d0b-a747-485b598d1a88","acronym":"","url":"https://clinicaltrials.gov/study/NCT03006302","created_at":"2024-01-03T19:17:30.474Z","updated_at":"2025-02-25T16:05:38.933Z","phase":"Phase 2","brief_title":"Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer","source_id_and_acronym":"NCT03006302","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" STAT6","pipe":"","alterations":" ","tags":["STAT6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cyclophosphamide • epacadostat (INCB024360) • CRS-207 • GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells)"],"overall_status":"Completed","enrollment":" Enrollment 41","initiation":"Initiation: 01/31/2018","start_date":" 01/31/2018","primary_txt":" Primary completion: 08/22/2023","primary_completion_date":" 08/22/2023","study_txt":" Completion: 08/05/2024","study_completion_date":" 08/05/2024","last_update_posted":"2024-10-08"},{"id":"786f4600-19b5-4661-828d-06dd8c75ce47","acronym":"QuEST1","url":"https://clinicaltrials.gov/study/NCT03493945","created_at":"2021-12-08T18:56:16.054Z","updated_at":"2024-07-02T16:34:37.137Z","phase":"Phase 1/2","brief_title":"Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)","source_id_and_acronym":"NCT03493945 - QuEST1","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TMB • BRCA1 • BRCA2 • MSI • HRD","pipe":" | ","alterations":" TMB-H • MSI-H/dMMR","tags":["TMB • BRCA1 • BRCA2 • MSI • HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H • MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bintrafusp alfa (M7824) • epacadostat (INCB024360) • Anktiva (nogapendekin alfa inbakicept-pmln)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 05/01/2018","start_date":" 05/01/2018","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-06-07"},{"id":"43f66187-5b30-4357-8f5c-84f785cedc80","acronym":"POD1UM-204","url":"https://clinicaltrials.gov/study/NCT04463771","created_at":"2021-01-18T21:27:26.857Z","updated_at":"2024-07-02T16:34:37.736Z","phase":"Phase 2","brief_title":"Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.","source_id_and_acronym":"NCT04463771 - POD1UM-204","lead_sponsor":"Incyte Corporation","biomarkers":" PD-L1 • MSI • POLE","pipe":" | ","alterations":" PD-L1 expression • MSI-H/dMMR • FGFR mutation • FGFR1 mutation","tags":["PD-L1 • MSI • POLE"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • MSI-H/dMMR • FGFR mutation • FGFR1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pemazyre (pemigatinib) • Zynyz (retifanlimab-dlwr) • epacadostat (INCB024360) • tuparstobart (INCAGN2385) • verzistobart (INCAGN2390)"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 01/26/2021","start_date":" 01/26/2021","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2024-06-06"},{"id":"a93b5243-ffcf-4281-ad7f-e82de9d05c25","acronym":"NRG-GY016","url":"https://clinicaltrials.gov/study/NCT03602586","created_at":"2024-03-25T19:35:46.855Z","updated_at":"2024-07-02T16:35:01.710Z","phase":"Phase 2","brief_title":"Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer","source_id_and_acronym":"NCT03602586 - NRG-GY016","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CD8 • IDO1","pipe":"","alterations":" ","tags":["PD-L1 • CD8 • IDO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • epacadostat (INCB024360)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 14","initiation":"Initiation: 12/21/2018","start_date":" 12/21/2018","primary_txt":" Primary completion: 02/01/2021","primary_completion_date":" 02/01/2021","study_txt":" Completion: 09/22/2024","study_completion_date":" 09/22/2024","last_update_posted":"2024-05-23"},{"id":"7bc669f9-70e9-4c55-a53a-75abe050ae78","acronym":"","url":"https://clinicaltrials.gov/study/NCT02042430","created_at":"2021-01-18T09:22:47.961Z","updated_at":"2024-07-02T16:35:15.364Z","phase":"Phase 1","brief_title":"Epacadostat Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT02042430","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IDO1","pipe":" | ","alterations":" IDO1 expression","tags":["IDO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDO1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e epacadostat (INCB024360)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 17","initiation":"Initiation: 08/25/2014","start_date":" 08/25/2014","primary_txt":" Primary completion: 03/31/2016","primary_completion_date":" 03/31/2016","study_txt":" Completion: 03/07/2025","study_completion_date":" 03/07/2025","last_update_posted":"2024-03-11"},{"id":"ab2260cd-5669-4294-b37f-0a90c1cf658a","acronym":"","url":"https://clinicaltrials.gov/study/NCT03196232","created_at":"2021-01-18T15:45:38.890Z","updated_at":"2025-02-25T16:06:27.137Z","phase":"Phase 2","brief_title":"Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer","source_id_and_acronym":"NCT03196232","lead_sponsor":"George Albert Fisher","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • epacadostat (INCB024360)"],"overall_status":"Completed","enrollment":" Enrollment 3","initiation":"Initiation: 09/13/2017","start_date":" 09/13/2017","primary_txt":" Primary completion: 05/29/2018","primary_completion_date":" 05/29/2018","study_txt":" Completion: 05/29/2018","study_completion_date":" 05/29/2018","last_update_posted":"2024-01-23"},{"id":"4ea15fcf-831f-46e9-9dc2-2559534f64cf","acronym":"","url":"https://clinicaltrials.gov/study/NCT03217669","created_at":"2021-01-18T15:52:36.643Z","updated_at":"2024-07-02T16:35:49.105Z","phase":"Phase 1","brief_title":"Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy","source_id_and_acronym":"NCT03217669","lead_sponsor":"Chao Huang","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR mutation • EGFR T790M","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR T790M"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sirolimus • epacadostat (INCB024360)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 02/22/2018","start_date":" 02/22/2018","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2023-05-02"},{"id":"1cfc9dae-087d-4a45-888a-feae0e1a43ee","acronym":"","url":"https://clinicaltrials.gov/study/NCT02166905","created_at":"2021-01-18T10:05:33.255Z","updated_at":"2024-07-02T16:35:54.811Z","phase":"Phase 1/2","brief_title":"DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission","source_id_and_acronym":"NCT02166905","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" CTAG1B • CD4 • CTAG2","pipe":"","alterations":" ","tags":["CTAG1B • CD4 • CTAG2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e epacadostat (INCB024360) • Hiltonol (poly-ICLC) • rasdegafusp alfa (CDX-1401)"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 10/10/2014","start_date":" 10/10/2014","primary_txt":" Primary completion: 08/20/2020","primary_completion_date":" 08/20/2020","study_txt":" Completion: 08/20/2020","study_completion_date":" 08/20/2020","last_update_posted":"2023-02-24"},{"id":"28520e3b-b67e-4eaa-88df-4b31a3271f54","acronym":"KEYNOTE-434","url":"https://clinicaltrials.gov/study/NCT02862457","created_at":"2021-01-18T14:03:08.705Z","updated_at":"2024-07-02T16:36:05.171Z","phase":"Phase 1","brief_title":"Study of Epacadostat (INCB024360) Alone and In Combination With Pembrolizumab (MK-3475) With Chemotherapy and Pembrolizumab Without Chemotherapy in Participants With Advanced Solid Tumors (MK-3475-434)","source_id_and_acronym":"NCT02862457 - KEYNOTE-434","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" EGFR • PD-L1 • ALK • IDO1","pipe":" | ","alterations":" IDO1 expression","tags":["EGFR • PD-L1 • ALK • IDO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDO1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • epacadostat (INCB024360)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 08/23/2016","start_date":" 08/23/2016","primary_txt":" Primary completion: 11/20/2020","primary_completion_date":" 11/20/2020","study_txt":" Completion: 11/20/2020","study_completion_date":" 11/20/2020","last_update_posted":"2022-08-19"},{"id":"ab27dcea-9b3e-4839-b5b8-bb5ab41a3775","acronym":"","url":"https://clinicaltrials.gov/study/NCT03592407","created_at":"2021-01-18T17:40:05.015Z","updated_at":"2024-07-02T16:36:15.867Z","phase":"Phase 2","brief_title":"Epacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III Esophageal or Gastroesophageal Cancer","source_id_and_acronym":"NCT03592407","lead_sponsor":"City of Hope Medical Center","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • epacadostat (INCB024360)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/01/2018","start_date":" 07/01/2018","primary_txt":" Primary completion: 04/01/2020","primary_completion_date":" 04/01/2020","study_txt":" Completion: 04/01/2020","study_completion_date":" 04/01/2020","last_update_posted":"2022-03-08"},{"id":"200995be-952b-4f51-b86f-819490f5de00","acronym":"KEYNOTE-037","url":"https://clinicaltrials.gov/study/NCT02178722","created_at":"2021-01-18T10:09:45.381Z","updated_at":"2025-02-25T16:13:55.509Z","phase":"Phase 1/2","brief_title":"Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers","source_id_and_acronym":"NCT02178722 - KEYNOTE-037","lead_sponsor":"Incyte Corporation","biomarkers":" HER-2 • BRAF • ER • ALK • PGR • MSI","pipe":" | ","alterations":" BRAF V600E • EGFR mutation • MSI-H/dMMR • HER-2 negative • BRAF V600 • ALK positive • ALK fusion","tags":["HER-2 • BRAF • ER • ALK • PGR • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • EGFR mutation • MSI-H/dMMR • HER-2 negative • BRAF V600 • ALK positive • ALK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • epacadostat (INCB024360)"],"overall_status":"Completed","enrollment":" Enrollment 444","initiation":"Initiation: 07/17/2014","start_date":" 07/17/2014","primary_txt":" Primary completion: 11/26/2018","primary_completion_date":" 11/26/2018","study_txt":" Completion: 11/06/2020","study_completion_date":" 11/06/2020","last_update_posted":"2022-02-14"},{"id":"1456df8e-ecc7-4a0f-9bbe-6f6ea46baff4","acronym":"KEYNOTE-715-06","url":"https://clinicaltrials.gov/study/NCT03322566","created_at":"2021-01-18T16:24:13.691Z","updated_at":"2025-02-25T16:07:03.389Z","phase":"Phase 2","brief_title":"A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)","source_id_and_acronym":"NCT03322566 - KEYNOTE-715-06","lead_sponsor":"Incyte Corporation","biomarkers":" EGFR • ALK • ROS1","pipe":" | ","alterations":" EGFR mutation • ALK translocation","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • paclitaxel • epacadostat (INCB024360)"],"overall_status":"Completed","enrollment":" Enrollment 233","initiation":"Initiation: 01/09/2018","start_date":" 01/09/2018","primary_txt":" Primary completion: 12/13/2018","primary_completion_date":" 12/13/2018","study_txt":" Completion: 10/16/2020","study_completion_date":" 10/16/2020","last_update_posted":"2022-01-24"},{"id":"eb576b9b-6b41-43aa-8151-b2af6e838ffd","acronym":"KEYNOTE-654-05","url":"https://clinicaltrials.gov/study/NCT03322540","created_at":"2021-01-18T16:24:12.771Z","updated_at":"2025-02-25T16:07:02.669Z","phase":"Phase 2","brief_title":"Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)","source_id_and_acronym":"NCT03322540 - KEYNOTE-654-05","lead_sponsor":"Incyte Corporation","biomarkers":" EGFR • PD-L1 • ALK • ROS1","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation • ALK translocation","tags":["EGFR • PD-L1 • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • epacadostat (INCB024360)"],"overall_status":"Completed","enrollment":" Enrollment 154","initiation":"Initiation: 12/15/2017","start_date":" 12/15/2017","primary_txt":" Primary completion: 01/10/2019","primary_completion_date":" 01/10/2019","study_txt":" Completion: 11/09/2020","study_completion_date":" 11/09/2020","last_update_posted":"2022-01-24"},{"id":"0353efa0-6275-454b-b1f8-30480e7f3f34","acronym":"KEYNOTE-672","url":"https://clinicaltrials.gov/study/NCT03361865","created_at":"2021-01-18T16:35:38.933Z","updated_at":"2025-02-25T16:07:16.351Z","phase":"Phase 3","brief_title":"Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)","source_id_and_acronym":"NCT03361865 - KEYNOTE-672","lead_sponsor":"Incyte Corporation","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • epacadostat (INCB024360)"],"overall_status":"Completed","enrollment":" Enrollment 93","initiation":"Initiation: 12/04/2017","start_date":" 12/04/2017","primary_txt":" Primary completion: 08/09/2018","primary_completion_date":" 08/09/2018","study_txt":" Completion: 08/04/2020","study_completion_date":" 08/04/2020","last_update_posted":"2021-12-16"},{"id":"eed84d27-1aaf-4918-a003-e647ca7b4abe","acronym":"","url":"https://clinicaltrials.gov/study/NCT04231864","created_at":"2021-01-18T20:35:12.024Z","updated_at":"2025-02-25T15:09:01.269Z","phase":"Phase 2","brief_title":"Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer","source_id_and_acronym":"NCT04231864","lead_sponsor":"Alain Algazi","biomarkers":" IDO1","pipe":"","alterations":" ","tags":["IDO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • epacadostat (INCB024360)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/01/2020","start_date":" 12/01/2020","primary_txt":" Primary completion: 04/01/2022","primary_completion_date":" 04/01/2022","study_txt":" Completion: 04/01/2024","study_completion_date":" 04/01/2024","last_update_posted":"2020-10-26"},{"id":"fc95a8c1-3e32-4713-a0ea-6f8ada58203a","acronym":"CheckMate 9NA","url":"https://clinicaltrials.gov/study/NCT03342352","created_at":"2021-01-18T16:30:32.853Z","updated_at":"2025-02-25T14:37:40.640Z","phase":"Phase 3","brief_title":"Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)","source_id_and_acronym":"NCT03342352 - CheckMate 9NA","lead_sponsor":"Incyte Corporation","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Erbitux (cetuximab) • cisplatin • carboplatin • 5-fluorouracil • epacadostat (INCB024360)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/15/2017","start_date":" 12/15/2017","primary_txt":" Primary completion: 04/20/2018","primary_completion_date":" 04/20/2018","study_txt":" Completion: 04/20/2018","study_completion_date":" 04/20/2018","last_update_posted":"2019-12-20"},{"id":"4b0f6cb1-7aff-4d10-960d-2eaaf780f325","acronym":"","url":"https://clinicaltrials.gov/study/NCT02364076","created_at":"2021-01-18T11:15:21.067Z","updated_at":"2025-02-25T16:14:28.467Z","phase":"Phase 2","brief_title":"Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma","source_id_and_acronym":"NCT02364076","lead_sponsor":"Georgetown University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • epacadostat (INCB024360)"],"overall_status":"Unknown status","enrollment":" Enrollment 45","initiation":"Initiation: 03/01/2015","start_date":" 03/01/2015","primary_txt":" Primary completion: 06/01/2019","primary_completion_date":" 06/01/2019","study_txt":" Completion: 12/01/2021","study_completion_date":" 12/01/2021","last_update_posted":"2019-12-13"},{"id":"555454ba-141a-407e-8e64-d23c36651dd1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03432676","created_at":"2021-01-18T16:55:55.122Z","updated_at":"2024-07-02T16:36:59.192Z","phase":"Phase 2","brief_title":"Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer","source_id_and_acronym":"NCT03432676","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRCA1 • ATM • BRCA • RAD51","pipe":" | ","alterations":" ATM mutation • PALB2 mutation • BRCA mutation • RAD51 mutation","tags":["BRCA1 • ATM • BRCA • RAD51"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • PALB2 mutation • BRCA mutation • RAD51 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • epacadostat (INCB024360)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/31/2019","start_date":" 07/31/2019","primary_txt":" Primary completion: 04/30/2020","primary_completion_date":" 04/30/2020","study_txt":" Completion: 04/30/2021","study_completion_date":" 04/30/2021","last_update_posted":"2019-05-30"},{"id":"e80b666d-efe1-47eb-b97b-2924543e0154","acronym":"","url":"https://clinicaltrials.gov/study/NCT03310567","created_at":"2021-01-18T16:20:59.239Z","updated_at":"2024-07-02T16:37:06.374Z","phase":"Phase 2","brief_title":"A Study of Pembrolizumab in Combination With Epacadostat in Women With Recurrent/Metastatic Endometrial Carcinoma","source_id_and_acronym":"NCT03310567","lead_sponsor":"Fox Chase Cancer Center","biomarkers":" MSI","pipe":"","alterations":" ","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • epacadostat (INCB024360)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/01/2018","start_date":" 09/01/2018","primary_txt":" Primary completion: 09/10/2018","primary_completion_date":" 09/10/2018","study_txt":" Completion: 09/10/2018","study_completion_date":" 09/10/2018","last_update_posted":"2018-10-09"},{"id":"00b90302-b8da-4837-b07a-b81c6ce45570","acronym":"","url":"https://clinicaltrials.gov/study/NCT03182894","created_at":"2021-01-18T15:41:46.268Z","updated_at":"2025-02-25T16:06:24.006Z","phase":"Phase 1/2","brief_title":"Epacadostat in Combination With Pembrolizumab and Azacitidine in Subjects With Metastatic Colorectal Cancer","source_id_and_acronym":"NCT03182894","lead_sponsor":"James J Lee","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • azacitidine • epacadostat (INCB024360)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/30/2018","start_date":" 09/30/2018","primary_txt":" Primary completion: 07/30/2019","primary_completion_date":" 07/30/2019","study_txt":" Completion: 07/30/2020","study_completion_date":" 07/30/2020","last_update_posted":"2018-08-28"},{"id":"243ba471-ed4f-4827-a927-eef176ee41a7","acronym":"","url":"https://clinicaltrials.gov/study/NCT01961115","created_at":"2021-03-25T17:09:12.570Z","updated_at":"2024-07-02T16:37:10.185Z","phase":"Phase 2","brief_title":"Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma","source_id_and_acronym":"NCT01961115","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" BRAF • CD8 • IFNG • CTLA4 • IDO1 • CD4","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • CD8 expression • IDO1 expression","tags":["BRAF • CD8 • IFNG • CTLA4 • IDO1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • CD8 expression • IDO1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e epacadostat (INCB024360)"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 09/13/2013","start_date":" 09/13/2013","primary_txt":" Primary completion: 10/31/2016","primary_completion_date":" 10/31/2016","study_txt":" Completion: 05/18/2017","study_completion_date":" 05/18/2017","last_update_posted":"2018-06-08"},{"id":"43cb05d3-4068-4a7f-8636-f18ceb4e8dbd","acronym":"","url":"https://clinicaltrials.gov/study/NCT02118285","created_at":"2021-01-18T09:48:21.451Z","updated_at":"2024-07-02T16:37:15.812Z","phase":"Phase 1","brief_title":"Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer","source_id_and_acronym":"NCT02118285","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • epacadostat (INCB024360) • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 2","initiation":"Initiation: 07/28/2014","start_date":" 07/28/2014","primary_txt":" Primary completion: 11/12/2015","primary_completion_date":" 11/12/2015","study_txt":" Completion: 11/12/2015","study_completion_date":" 11/12/2015","last_update_posted":"2017-12-05"}]